By staff writers

October 9, 2018 -- Imaging agent developer ImaginAb has signed a multiyear, nonexclusive licensing agreement with pharmaceutical firm Merck.

Under the deal, Merck -- known as MSD outside of the U.S. and Canada -- will purchase ImaginAb's CD8 T-cell PET imaging agent for use in immuno-oncology clinical trials involving multiple types of cancer. Furthermore, Merck is making an equity investment in ImaginAb's series B financing round, according to ImaginAb.

Copyright © 2018

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking